Adalimumab treatment arm(AbbVie)은 Psoriasis 표적 항체로, Psoriasis; Cardiovascular Diseases 영역에서 개발·상용화 중입니다. 작용기전: targeted disruption of the physiological pathway. FDA 승인 또는 승인 단계 프로그램입니다. 대표 임상 효능: ORR 2% (ClinicalTrials.gov NCT00808509). 차별점: Novel Hidradenitis Suppurativa-Specific Investigator Global Assessment for Use in Interventional Trials.
Psoriasis
Psoriasis; Cardiovascular Diseases
Active
bispecific antibodies
cleavable linkers
Novel Hidradenitis Suppurativa-Specific Investigator Global Assessment for Use in Interventional Trials
targeted disruption of the physiological pathway
immune-mediated inflammatory diseases: a systematic review and network meta-analysis
biomarker-stratified multicentre randomised controlled trial, which the baseline proportion of CD4+T cells wi
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Adalimumab treatment arm(AbbVie)은 Psoriasis 표적 항체로, Psoriasis; Cardiovascular Diseases 영역에서 개발·상용화 중입니다. 작용기전: targeted disruption of the physiological pathway. FDA 승인 또는 승인 단계 프로그램입니다. 대표 임상 효능: ORR 2% (ClinicalTrials.gov NCT00808509). 차별점: Novel Hidradenitis Suppurativa-Specific Investigator Global Assessment for Use in Interventional Trials.
Psoriasis
Psoriasis; Cardiovascular Diseases
Active
bispecific antibodies
cleavable linkers
Novel Hidradenitis Suppurativa-Specific Investigator Global Assessment for Use in Interventional Trials
targeted disruption of the physiological pathway
immune-mediated inflammatory diseases: a systematic review and network meta-analysis
biomarker-stratified multicentre randomised controlled trial, which the baseline proportion of CD4+T cells wi
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.